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A B S T R A C T
Psoriasis is a chronic, relapsing, inflammatory and hyperproliferative skin disorder. The levels of acute phase pro-
teins are suggested to be elevated in those patients with acute disease. The expression of selected acute phase proteins as
the parameters of humoral immunity has been analyzed in 70 patients with acute psoriasis and 40 healthy controls. The
aim was to evaluate the inflammatory response in the exacerbation of psoriasis and to determine the correlation of these
objective inflammatory parameters with clinical features of disease activity. Main demographic and epidemiologic fea-
tures were, as well, analysed. The plasma levels of C-reactive protein (CRP) (c2 = 23.61; p<0.005), and alpha1-acid
glycoprotein (a1-AGP) (c2 = 7.,42; p<0.01) were significantly increased in those patients with acute phase of the disease
compared to healthy controls. Our results suggest that psoriasis is an inflammatory disease and therefore its worsening
seemed to be linked to the increase in the inflammatory response. It seems that CRP and al-AGP levels could serve as im-
portant prognostic factors for the worsening of psoriasis.
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Introduction
Psoriasis is histologically characterized by significant
epidermal keratinocyte hyperplasia and it has been sug-
gested that impaired epidermal proliferation and kera-
tinocyte differentiation, as well as increased epidermal
turnover play a role in the pathogenesis of the disease1,2.
Psoriasis is defined as a chronic, relapsing, inflammatory
and hyperproliferative skin disorder characterized by
sharply defined erythematosquamous lesions3. The pa-
thogenesis of the disease remains enigmatic. It is an in-
flammatory disease in which abnormal individual im-
mune response plays an important role4. The genetic
predisposition, certain Human Leukocyte Antigens (HLA)
haplotype (HLA-Cw*0602) in association with environ-
mental factors are involved in the immunopathogenesis
of psoriasis5. The environmental triggering factors are
largely unknown, but it is well known that bacterial in-
fections, such as Streptococcal infection, may induce or
aggravate psoriasis by antigen-mediated induction of im-
munopathological reactivity.
An acute phase of psoriasis can be induced by inflam-
matory cytokines that play an important role in the
pathogenesis of the disease. Activation of the acute phase
reaction by pro-inflammatory cytokines is responsible
for the development of systemic symptoms, such as in-
creased temperature, arthropaty and general pruritus, in
severe forms of psoriasis, like arthorpatic and pustular
psoriasis. It has been suggested that acute phase proteins
are mostly elevated in the acute phase of the disease,
while still present in phases of clinical remission. Among
the large group of acute phase reactants, C-reactive pro-
tein (CRP), alpha2-macroglobulin (a2-MG), alpha1-anti-
trypsin (a1-AT), and alpha1-acid glycoprotein (a1-AGP)
may be of special interest in psoriasis.
In this study, we examined the expression of selected
acute phase proteins as the parameters of humoral im-
munity in acute phase of the disease in order to deter-
mine the correlation of the inflammatory response and
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the exacerbation of psoriasis. We have also analyzed de-
mographic and epidemiologic features of psoriatic pa-
tients in order to determine a genetic predisposition for
the disease.
Materials and Methods
We included in this study 110 patients, of which 40
healthy volunteer blood donors (6 female, 34 male) and 70
patients diagnosed with psoriasis (34 female, 36 male),
treated at the Department of Dermatovenerology, Univer-
sity Hospital Osijek, Department of Dermatovenerology,
University Hospital Zagreb and Department of Derma-
tovenerology, Clinical Hospital »Sestre Milosrdnice«, Zag-
reb, between 2005 and 2007, irrespective of age and sex.
Diagnostic criteria for psoriasis included typical clinical
features which were then confirmed histologically.
The average age of psoriatic patients was 51.0 ± 12.6
years (48.7 ± 12.5 years for male, 53.4 ± 12.4 years for fe-
male) and of healthy controls 36.7 ± 10.0 years (37.2 ± 9.4
years for male, 33.7 ± 13.8 years for female). The healthy
control group consisted of significantly younger patients
compared to the group of patients with psoriasis (p<
0.05).
Patients with psoriasis were clinically carefully evalu-
ated. Severity of psoriasis was determined quantitatively
based on the percentage of skin involvement and was
graded as follows: minimal skin involvement (less than
9% of skin involved), average skin involvement (between
10% and 29% of skin involved) and extreme skin involve-
ment (more than 30% of skin involved). The average per-
centage of the involved skin in psoriatic patients was
51.4% (36) and the extreme skin involvement was ob-
served in 48.6% (34) patients. The estimated median skin
involvement in psoriasis was 32.93% (SD 21.63). The
pustular psoriasis was not included in the research.
Blood samples were obtained from patients with pso-
riasis in the active stage of the disease and healthy con-
trol group. Plasma concentrations of CRP, a2-MG, a1-AT
and a1-AGP were analyzed. In vitro diagnostic methods
were used for the quantitative determination of a1-AT,
a2-AGP and a2-MG in human serum such as nephe-
lometry using the Nephelometer- BN ProSpec (BN*Sys-
tems, Dade Behring Marburg GmbH, USA). The assay
protocols for BN*Systems are given in the Instruction
Manual and software of the instrument. All steps are
performed automatically by the system. (Reagents-mate-
rials provided: N Antiserum to Human a1-Antitrypsin,
Code No. OSAZ; N Antiserum to Human a2-Macro-
globulin, Code No. OSAM or N Antiserum to Human
a1-acid Glycoprotein, Code No. OSAW).
CRP was determined by immuno-turbidimetric test
for the quantitative determination of C-reactive protein
(CRP) in human serum and plasma on OLYMPUS analy-
ses (CRP Latex-OSR6199). Calibration was for Normal
application with calibrator: Olympus CRP Latex Calibra-
tor Normal Set (Cat. No.ODC0026). The calibrator CRP
values are traceable to IFCC (International Federation of
Clinical Chemistry) standard CRM 470.
The differences between groups were analysed using
the Mann-Whithey U test and Chi-square test. P values
of less than 0.05 were considered statistically significant.
Results
A familiar distribution pattern for psoriasis has been
found in 26 (37.14%) patients with psoriasis. A signifi-
cantly higher genetic prevalence was found in patients
with type I psoriasis (22 patients, 31.4%), compared to
patients with type II psoriasis (4 patients, 5.7%) (c2=
9.92; p<0.05). It was observed that heredity is more of-
ten related to the father’s side of the family (11 of totally
26 patients) compared to mother’s side (6 of totally 26
patients) but the difference was not statistically signifi-
cant (c2=1,39; p>0.05) due to the small group of pa-
tients.
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TABLE 1
PLASMA LEVELS OF ACUTE PHASE PROTEINS IN PSORIASIS AND HEALTHY CONTROL GROUP
Diagnosis
Normal Decreased Increased p*
N % N % N %
a2-MG Psoriasis 51 72.9 16* 22.9 3* 4.3 >0.05
Control 37 92.5 3 7.5 0 0.0
a1-AT Psoriasis 58 82.9 7* 10.0 5* 7.1 >0.10
Control 35 87.5 5 12.5 0 0.0
a1-AGP Psoriasis 48 68.6 2 2.9 20* 28.6 <0.01
Control 36 90.0 2 5.0 2 5.0
CRP Psoriasis 38 54.3 – – 32* 45.7 <0.005
Control 40 100.0 – – – –
a1-AGP – Alpha1- acid glycoprotein, a2-MG – Alpha2-macroglobulin, a1-AT – Alpha1-antitrypsin
c2 test * p values of less than 0.05 were considered statistically significant.
The detected plasma levels of CRP, a2-MG, a1-AT and
a1-AGP in the psoriatic patients during the acute disease
and in healthy controls are shown in Table 1. There was
a significant increase in the plasma level of CRP (c2=
23.61; p<0.005), and a1-AGP (c2=7.42; p<0.01) in acute
phase of the disease compared to control group. On the
other hand, levels of alpha1-AT (c2=1.57; p>0.1 for in-
creased values and c2=0.008; p>0.1 for decreased val-
ues) and 2-MG (c2=0.51; p>0.1 for increased values and
c2=3.19; p>0.05 for decreased values) were generally
within the normal ranges and were not significantly dif-
ferent from the levels detected in the control group.
There was no difference observed in clinical findings
between patients with the type I and type II psoriasis
(p>0.05).
Discussion
Psoriasis is a chronic and recurrent inflammatory
skin disease. It is a common skin disorder, affecting
about 1–3% of the population3,5. Some 7–42% of patients
with psoriasis develop either a peripheral or axial inflam-
matory arthritis6. The inflammatory response represents
a fundamental ability of the organism to protect itself
from different infectious agents and injury. In order to
evaluate the inflammatory response in the acute phase of
psoriasis and to determine a possible prognostic signifi-
cance of acute phase proteins, we have analyzed their ex-
pression during the exacerbation of the disease. Ana-
lyzed acute phase proteins and cytokines involved in the
development of skin inflammation are closely related.
We have detected elevated peripheral blood levels of
two acute phase proteins, CRP and a1-AGP in psoriatic
patients during the acute phase of the disease. These re-
sults are in accordance with previously published re-
sults7–11. Some authors detected increased values of a2-
MG in patients with psoriasis7,9,12,13. On the contrary, we
have found increased values of a2-MG in only several pa-
tients with psoriasis, but without a statistically signifi-
cant difference compared to the healthy control group.
Therefore, we suggest that further studies are needed in
order to elucidate these differences in a2-MG values in
psoriatic patients.
CRP is regarded as the most sensitive, but as well, not
specific indicator of inflammation of various origins, in-
cluding trauma and cancer7. Its significant function is in
binding the altered biological material in peripheral
blood, by enhancing the reactions of blocking, detoxi-
cation and elimination7. Since, elevated concentration of
CRP in peripheral blood is a result of interaction be-
tween pro-inflammatory cytokines, their receptors and
inhibitory factors, the changes in CRP concentration ob-
served in various stages of disease activity are indirect
indication of the role of cytokines in the pathogenetic
process. On the other hand, a2-MG is a multifunctional
binding protein that binds cytokines, toxins, bacterial
and viral proteins, zinc and hormones14. The most impor-
tantly a2-MG has a capacity to down-regulate the activ-
ity of proteolytic enzymes whose production is increased
during inflammatory response including immunopatho-
logical inflammation such as psoriasis9.
The concentration and glycosylation of a1-AGP has
been shown to alter significantly during inflammation10,11.
A definitive physiological role of this acute phase proteins
remains elusive and is the subject of extensive investiga-
tion. It has been suggested that contrary to normal plas-
ma a1-AGP, rheumatoid a1-AGP within synovial fluid
might be inadequate to prevent excessive cartilage de-
struction and might exacerbate the disease process11.
Compared to the previously suggested prognostic sig-
nificance of elastase/alpha1-AT levels for the worsening of
psoriasis12, we have not detected elevated level of alpha1-
AT in the acute phase of disease, as well as, no correlation
with clinical disease activity. These findings are in accor-
dance with previous research showing alpha1-AT not to
be as good, specific and sensitive inflammatory marker for
diagnosis and follow up of the disease activity as plasma
polymorphonuclear leukocyte elastase level13.
As suggested earlier, our results confirm that geneti-
cally predisposed psoriasis (type I) is characterized by an
early onset of the disease compared to the sporadic form
(type II) of psoriasis, although there were no statistically
significant differences found in respect to clinical and
serological findings between these two groups, as shown
in previous research15, that would permit us to identify
any particular subset. Our results suggest that psoriasis
is an inflammatory disease and its worsening seemed to
be the result of increased inflammatory response. We
suggest that CRP and a1-AGP levels are of prognostic
significance for the worsening of psoriasis.
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PROTEINI AKUTNE FAZE U PSORIJAZI
S A @ E T A K
Psorijaza je kroni~na, recidiviraju}a, hiperproliferativna bolest ko`e. Predlo`eno je da su vrijednosti bjelan~evina
akutne faze upale povi{eni u egzacerbaciji bolesti. Analizirane su vrijednosti pojedinih bjelan~evina akutne faze upale
kao parametri humoralne imunosti u 70 bolesnika s pogor{anjem simptoma psorijaze i 40 zdravih ispitanika, u cilju
evaluacije upalnog odgovora u pogor{anju psorijaze i utvrdila povezanost ovih objektivnih parametara upale s klini~ki
utvr|enom aktivnosti bolesti. Tako|er, analizirani su glavne demografske i epidemiolo{ke karakteristike u bolesnika s
psorijazom u svrhu odre|ivanja obiteljske razdiobe bolesti. Utvr|en je zna~ajan porast vrijednosti C-reaktivnog pro-
teina (CRP) (c2 =23,61; p<0,005) i alfa1-kiselog glikoproteina (a1-AGP) (c2 =7,42; p<0,01) u fazi pogor{anja bolesti u
usporedbi s vrijednostima u zdravih ispitanika. Na{i rezultati potvr|uju da je psorijaza upalna bolest i pogor{anje kli-
ni~kih manifestacija povezano je s nagla{enim upalnim odgovorom. Predla`emo da vrijednosti CRP i a1-AGP imaju
prognosti~ko zna~enje u egzacerbaciji psorijaze.
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